These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340 [TBL] [Abstract][Full Text] [Related]
3. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. Ivachtchenko AV; Lavrovsky Y; Okun I J Alzheimers Dis; 2016 May; 53(2):583-620. PubMed ID: 27232215 [TBL] [Abstract][Full Text] [Related]
4. AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease. Ivachtchenko AV; Lavrovsky Y; Ivanenkov YA Mol Pharm; 2016 Mar; 13(3):945-63. PubMed ID: 26886442 [TBL] [Abstract][Full Text] [Related]
5. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease. Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049 [TBL] [Abstract][Full Text] [Related]
6. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250 [TBL] [Abstract][Full Text] [Related]
7. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Gravius A; Laszy J; Pietraszek M; Sághy K; Nagel J; Chambon C; Wegener N; Valastro B; Danysz W; Gyertyán I Behav Pharmacol; 2011 Apr; 22(2):122-35. PubMed ID: 21301322 [TBL] [Abstract][Full Text] [Related]
8. 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia. de Bruin NM; Kruse CG Curr Pharm Des; 2015; 21(26):3739-59. PubMed ID: 26044973 [TBL] [Abstract][Full Text] [Related]
9. SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization. Nirogi R; Abraham R; Benade V; Medapati RB; Jayarajan P; Bhyrapuneni G; Muddana N; Mekala VR; Subramanian R; Shinde A; Kambhampati R; Jasti V Behav Pharmacol; 2019 Feb; 30(1):16-35. PubMed ID: 29847336 [TBL] [Abstract][Full Text] [Related]
10. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Yamazaki M; Harada K; Yamamoto N; Yarimizu J; Okabe M; Shimada T; Ni K; Matsuoka N Eur Neuropsychopharmacol; 2014 Oct; 24(10):1698-708. PubMed ID: 25108314 [TBL] [Abstract][Full Text] [Related]
11. 1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists. Fabritius CH; Pesonen U; Messinger J; Horvath R; Salo H; Gałęzowski M; Galek M; Stefańska K; Szeremeta-Spisak J; Olszak-Płachta M; Buda A; Adamczyk J; Król M; Prusis P; Sieprawska-Lupa M; Mikulski M; Kuokkanen K; Chapman H; Obuchowicz R; Korjamo T; Jalava N; Nowak M Bioorg Med Chem Lett; 2016 Jun; 26(11):2610-5. PubMed ID: 27117428 [TBL] [Abstract][Full Text] [Related]
12. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589 [TBL] [Abstract][Full Text] [Related]
13. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon. Okun I; Tkachenko SE; Khvat A; Mitkin O; Kazey V; Ivachtchenko AV Curr Alzheimer Res; 2010 Mar; 7(2):97-112. PubMed ID: 19939222 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998 [TBL] [Abstract][Full Text] [Related]
15. The selective 5-HT6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment. de Bruin NMWJ; van Loevezijn A; Wicke KM; de Haan M; Venhorst J; Lange JHM; de Groote L; van der Neut MAW; Prickaerts J; Andriambeloson E; Foley AG; van Drimmelen M; van der Wetering M; Kruse CG Neurobiol Learn Mem; 2016 Sep; 133():100-117. PubMed ID: 27344942 [TBL] [Abstract][Full Text] [Related]
16. Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats. Yamazaki M; Okabe M; Yamamoto N; Yarimizu J; Harada K J Pharmacol Sci; 2015 Mar; 127(3):362-9. PubMed ID: 25837935 [TBL] [Abstract][Full Text] [Related]
17. Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT Nirogi R; Shinde A; Kambhampati RS; Mohammed AR; Saraf SK; Badange RK; Bandyala TR; Bhatta V; Bojja K; Reballi V; Subramanian R; Benade V; Palacharla RC; Bhyrapuneni G; Jayarajan P; Goyal V; Jasti V J Med Chem; 2017 Mar; 60(5):1843-1859. PubMed ID: 28212021 [TBL] [Abstract][Full Text] [Related]